marked.bio

Company

MediLink Therapeutics

4 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

YL202 3ivonescimab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

4 of 4 trials shown

  1. Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

    Recruiting Phase 3 MediLink Therapeutics Started 2026Primary completion 2028-08 NCT07416994

    YL202docetaxel

    …vanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

  2. A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

    Recruiting Phase 1/2 MediLink Therapeutics Started 2025Primary completion 2027-01 NCT07208773

    YL201ivonescimab

    Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC.

    EGFR exon 19 deletion / L858RAdvanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer

  3. A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

    Recruiting Phase 2 MediLink Therapeutics Started 2024Primary completion 2027-07 NCT06439771

    YL202

    Patients who are confirmed HR positive and HER2-Zero-expression and HER2-Low-expression.

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Locally Advanced or Metastatic Breast Cancer

  4. A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

    Active, not recruiting Phase 1 MediLink Therapeutics Started 2022Primary completion 2026-12 NCT05653752

    YL202

    Have a documentation of an EGFR-activating mutation (exon 19 deletion or L858R) detected from tumor tissue at diagnosis or thereafter.

    EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer, Breast Cancer